The 2nd Cell & Gene Therapy Regulatory Affairs Summit, scheduled for December 2-4 in Washington, D.C., highlights the rapid changes in the regulatory environment for cell and gene therapies (CGTs). The event comes at a crucial time, with new FDA leadership at CBER, draft guidance on post-approval CMC requirements, and increased scrutiny on potency assays. Additionally, global agencies like ANVISA and Health Canada are enhancing harmonization efforts, while ICH Q12 implementation progresses across modalities. These shifts underscore the need for regulatory professionals to stay abreast of changes to expedite approvals and ensure patient access to innovative therapies.
This summit offers a platform for regulatory professionals to delve into nonclinical, clinical, and CMC submissions. With over 80 experts sharing real-world case studies and actionable insights, attendees can gain valuable perspectives on key focus areas such as regulatory expectations for 2025 and beyond. The event provides a unique opportunity to engage with regulators, biotech leaders, and regulatory strategists, facilitating knowledge exchange and networking crucial for successful CGT development.
Whether participants are focused on early-stage IND preparation, late-stage BLA strategy, or post-market compliance, this summit equips them with the necessary knowledge, frameworks, and connections to navigate evolving regulatory requirements effectively. The insights shared at the event can aid professionals in accelerating the development and approval of CGTs, ultimately ensuring that these innovative therapies reach patients efficiently and safely.
Amidst the evolving regulatory landscape, the summit serves as a pivotal gathering for industry stakeholders to align strategies and best practices. By staying ahead of regulatory changes and engaging with peers and regulators, attendees can enhance their regulatory strategies and contribute to the advancement of CGT development. The event aims to foster collaboration, knowledge sharing, and innovation in the field of cell and gene therapies, ultimately driving the progress of these transformative technologies.
Key Takeaways:
– The 2nd Cell & Gene Therapy Regulatory Affairs Summit provides a crucial platform for professionals to navigate the rapidly changing regulatory landscape in the CGT space.
– With insights from regulators, industry leaders, and regulatory experts, attendees can gain valuable perspectives on key regulatory focus areas for 2025 and beyond.
– The summit equips participants with the knowledge, frameworks, and connections necessary to accelerate CGT development and ensure timely patient access to innovative therapies.
– By fostering collaboration and knowledge exchange, the event aims to drive innovation and regulatory excellence in the field of cell and gene therapies.
Tags: biotech, gene therapy, clinical trials, biosimilars, cell therapy, regulatory
Read more on pharmaphorum.com